Looks at whether GLP-1 drugs with ocrelizumab affect multiple sclerosis progression
Observes adults with multiple sclerosis taking ocrelizumab alongside GLP-1 drugs.
Plain-language title generated from the registry record
Registry title: People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
Key facts
- Where
- Chicago, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07207148, who can take part
Where in United States
- Northwestern Memorial HospitalChicago, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Northwestern University
- Trial code
- NCT07207148
- Record updated
- 17 March 2026
- Original description
The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not.Read full original descriptionShow less
People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists
The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not.
For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest.
For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score.
Inclusion: Diagnosis of MS (2019 revised McDonald criteria) of any type (PPMS, RRMS, SPMS) by a neurologist,; Adult age 18-70 years,; BMI >=24.0 kg/m2,; Taken at least one dose of Ocrelizumab prior to study entry,; EDSS <7.0,; Able to provide individual informed consent,; MRI available to confirm the diagnosis of MS.
Exclusion: Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,; Unclear documentation of MS diagnosis or prior or current MS treatment,; Recent major surgical procedure in the past 6 months,; Exposure to steroids (systemic) within the past 3 months,; Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, dementia, etc.),; Current clinical trial participant,; Unable to speak a language for which translation can be found in the hospital system,; Relapse within the past 3 months,; Not on Ocrelizumab in the past >9 months,; Moribund status,; Underweight or experiencing protein malnutrition,; Unable to complete the study activities for any reason as deemed by the study investigator; Additional Inclusion Criteria Aim 1:; Exposed to GLP-1 agonist treatment in the last 3 years or less, or starting on a GLP-1 agonist in the coming <3 months,; Willing to report monthly patient-reported outcomes remotely or in-person; Additional Inclusion Criteria Aim 2:; Able to present for baseline and follow up in person,; Unexposed to a GLP-1 agonist in the past year,; Starting on a GLP-1 agonist in the next <6 months,; Plan to be exposed to GLP-1 agonist for a minimum of 72 weeks following enrollment.